NASDAQ:PHAR Pharming Group (PHAR) Stock Price, News & Analysis $11.54 -0.63 (-5.18%) Closing price 11/20/2026 03:46 PM EasternExtended Trading$11.51 -0.03 (-0.29%) As of 11/20/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Pharming Group Stock (NASDAQ:PHAR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pharming Group alerts:Sign Up Key Stats Today's Range$11.30▼$11.9750-Day Range$9.11▼$13.2252-Week Range$9.11▼$21.34Volume10,505 shsAverage Volume17,084 shsMarket Capitalization$816.80 millionP/E Ratio36.06Dividend YieldN/APrice Target$39.67Consensus RatingModerate Buy Company Overview Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming also continues to develop medicines for rare diseases. The company serves patients in the United States, Europe and other markets through its commercial activities and partners. Its products and development programs focus on conditions for which treatment options can be limited.AI Generated. May Contain Errors. Read More Pharming Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScorePHAR MarketRank™: 3.79835791817 of 5 starsPharming Group scored higher than 76% of companies evaluated by MarketBeat, and ranked 119th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingPharming Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialPharming Group has a consensus price target of $39.67, representing about 243.7% upside from its current price of $11.54.Amount of Analyst CoveragePharming Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pharming Group's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth50.00% Earnings GrowthEarnings for Pharming Group are expected to grow by 50.00% in the coming year, from $0.34 to $0.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharming Group is 36.06, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharming Group is 36.06, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.45.Price to Book Value per Share RatioPharming Group has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the float of Pharming Group has been sold short.Short Interest Ratio / Days to CoverPharming Group has a short interest ratio ("days to cover") of 1.42, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharming Group has recently increased by 91.99%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharming Group does not currently pay a dividend.Dividend GrowthPharming Group does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment1.02 News SentimentPharming Group has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pharming Group this week, compared to 4 articles on an average week.Search Interest4 people have searched for PHAR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Pharming Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharming Group insiders have not sold or bought any company stock.Percentage Held by Insiders2.07% of the stock of Pharming Group is held by insiders.Percentage Held by Institutions0.03% of the stock of Pharming Group is held by institutions.Read more about Pharming Group's insider trading history. Receive PHAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHAR Stock News HeadlinesCritical Survey: Pharming Group (NASDAQ:PHAR) versus Yarrow Bioscience (NASDAQ:YARW)November 14, 2026 | americanbankingnews.comPharming to participate in fireside chat at Jefferies Global Healthcare Conference in LondonNovember 11, 2026 | globenewswire.comELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.November 21 at 1:00 AM | Paradigm Press (Ad)MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.November 6, 2026 | finance.yahoo.comMHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.November 6, 2026 | globenewswire.comPharming: 3 key takeaways for long-term investorsNovember 4, 2026 | msn.comPharming Group (PHAR): Joenja Gains Momentum And Ruconest Returns To GrowthOctober 28, 2026 | rttnews.comPharming Q3 Revenue Jumps 21%, CVID Data Due In NovemberOctober 28, 2026 | rttnews.comSee More Headlines PHAR Stock Analysis - Frequently Asked Questions How have PHAR shares performed this year? Pharming Group's stock was trading at $17.67 at the beginning of 2026. Since then, PHAR shares have decreased by 34.7% and is now trading at $11.54. How were Pharming Group's earnings last quarter? Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) posted its earnings results on Tuesday, October, 27th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.21 by $0.09. The business had revenue of $117.60 million for the quarter, compared to the consensus estimate of $117.60 million. Pharming Group had a net margin of 6.23% and a trailing twelve-month return on equity of 8.70%. Read the conference call transcript. When did Pharming Group IPO? Pharming Group (PHAR) raised $0 in an IPO on Wednesday, December 23rd 2020. The company issued 899,802 shares at $0.00 per share. How do I buy shares of Pharming Group? Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharming Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharming Group investors own include Pharming Group (PHGUF), NVIDIA (NVDA), Plug Power (PLUG), USA Rare Earth (USAR), Advanced Micro Devices (AMD), Verizon Communications (VZ) and Palantir Technologies (PLTR). Company Calendar Last Earnings10/27/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PHAR's financial health is in the Red zone, according to TradeSmith. PHAR has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PHAR CIK1828316 Webwww.pharming.com Phone31-71-524-7400FaxN/AEmployees407Year Founded1988Price Target and Rating Average Price Target for Pharming Group$39.67 High Price Target$41.00 Low Price Target$37.00 Potential Upside/Downside+243.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.32 Trailing P/E Ratio36.06 Forward P/E Ratio22.63 P/E GrowthN/ANet Income$2.85 million Net Margins6.23% Pretax Margin8.86% Return on Equity8.70% Return on Assets4.93% Debt Debt-to-Equity Ratio0.32 Current Ratio3.23 Quick Ratio2.65 Sales & Book Value Annual Sales$376.13 million Price / Sales2.17 Cash Flow$0.18 per share Price / Cash Flow62.78 Book Value$4.11 per share Price / Book2.81Miscellaneous Outstanding Shares70,780,000Free Float69,313,000Market Cap$816.80 million OptionableNot Optionable Beta-0.05 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:PHAR) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersGet your evenings backThe Instant Scanner delivers the night's qualifying setups with exact buy prices and defined exits, in minutes...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.